Icas ctos 2005 review of studies
This presentation is the property of its rightful owner.
Sponsored Links
1 / 11

ICAS: CTOS 2005 Review of Studies PowerPoint PPT Presentation


  • 48 Views
  • Uploaded on
  • Presentation posted in: General

ICAS: CTOS 2005 Review of Studies. U.S. NCI-funded Intergroup. ICAS: Mission and Vision. NCI-funded coalition of North American cooperative oncology groups with focus in Sarcoma Research

Download Presentation

ICAS: CTOS 2005 Review of Studies

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Icas ctos 2005 review of studies

ICAS:CTOS 2005 Review of Studies

U.S. NCI-funded Intergroup


Icas mission and vision

ICAS: Mission and Vision

  • NCI-funded coalition of North American cooperative oncology groups with focus in Sarcoma Research

  • Leverage fixed infrastructures ofSWOG, CALGB, ECOG, and NCI-Canadato advance publicly-funded sarcoma research


What is the role of icas

What is the Role of ICAS?

  • Differentiation of work from other smaller groups without NCI funding and with more restricted focus of activities

  • Where does national and international scale really need to be applied to advance research?


Strengths for nationally funded sarcoma research effort

Strengths for Nationally Funded Sarcoma Research Effort

  • Very large scale effectiveness studies

  • Casting a very broad net to include the entire continent of physicians and patients

  • Legitamacy and stability ofpublic sector funding through NCI


Review of icas studies

Review of ICAS Studies

  • S0033: randomized GIST testing Imatinib 400 v. 800

    • continuing molecular studies

    • survival long term

    • other sub-studies in progress


Icas studies metastatic disease

ICAS STUDIESMetastatic Disease

ICAS #SarcomaTargetAgent

S0330*MPNSTEGF-R erlotinib

S0345DFSPPDGF-R imatinib

S0346SynovialHER2 trastuzumab

S0505All STSVEGFR+ sorafenib

* First Stage accrual goal reached


Icas studies metastatic disease1

ICAS STUDIESMetastatic Disease

ICAS #SarcomaTargetInhibitor

S0423 ChondroMTAP pemetrexed

S0502 GIST KIT/PDGFR Imatinib

VEGF bevacizumab

S0416(COG) GIST(Pedi-AYA) KIT/PDGFR imatinib


The future of icas

The Future of ICAS

  • Choose carefully which trials require full scope of national group mechanism

  • Optimize efficiency for participation through inclusive investigator registration mechanism

    • test the function and promise of theClinical Trials Support Unit of NCI)


Z9031

Z9031

A randomized trial of preoperative radiation plus

surgery versus surgery alone for localized primary

retroperitoneal STS. P.W.T. Pisters, MD

Arm 1:Surgery

Patients with primary STS of the retroperitoneum or pelvis

R

A

N

D

O

M

I

Z

E

Arm 2:XRT plus Surgery

CTSU !!!

A C O S O G


Icas ctos 2005 review of studies

Z9001

Phase III randomized double-blind study ofadjuvant Imatinib versus placebo in patientsfollowing resection of primary GIST.Study Coordinator: Ronald DeMatteo, MD

Primary GIST > 3 cm

Successful

Use of CTSU

Decentralized

Registrations

Complete Gross Resection

Tumor KIT +

Randomize

Placebo

x 1 yr

Imatinib

x 1 yr


Acosog in development

ACOSOG in Development

Phase II evaluation of PET imaging as a predictor of response to neoadjuvant treatment for STS. Edward Cheng, MD (collaborative effort with ACRIN)

Neoadjuvant Rx

FDG-PET scan, routine staging studies

(MRI and CT)

Biopsy-

Confirmed

STS

Repeat FDG-PET

Wide local excision, histologic assessment of necrosis

A C O S O G


  • Login